Over the past decade, there have been profound shifts in clinical trial design. Phase II randomized studies, phase II/III and other adaptive designs, early surrogate end points, and prospective biomarker-based patient selection have all increased in popularity. We discuss these shifts in clinical trial designs that have increased efficiency in identifying which patients will benefit from specific treatments.
- Daniel J. Sargent
- Edward L. Korn
